Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

67 results about "PTPN1" patented technology

Tyrosine-protein phosphatase non-receptor type 1 also known as protein-tyrosine phosphatase 1B (PTP1B) is an enzyme that is the founding member of the protein tyrosine phosphatase (PTP) family. In humans it is encoded by the PTPN1 gene. PTP1B is a negative regulator of the insulin signaling pathway and is considered a promising potential therapeutic target, in particular for treatment of type 2 diabetes. It has also been implicated in the development of breast cancer and has been explored as a potential therapeutic target in that avenue as well.

Novel compounds for the treatment of cancer and metabolic diseases

PCT designated stage expiredWO2025016906A1Organic active ingredientsOrganic chemistryDiseasePTPN1
The present invention relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of PTPN2 and / or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of PTPN2 and / or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to processes for the preparation of said compounds.
Owner:KATHOLIEKE UNIV LEUVEN +1

Novel compounds for the treatment of cancer and metabolic diseases

PCT designated stage expiredWO2025016909A1Organic active ingredientsOrganic chemistryDiseasePTPN1
The present invention relates to novel compounds of formulae (I) and (III), to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of PTPN2 and / or PTPN 1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of PTPN2 and / or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to processes for the preparation of said compounds.
Owner:KATHOLIEKE UNIV LEUVEN +1

Protein tyrosine phosphatase inhibitors and uses thereof

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatases, such as protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions that respond favorably to PTPN1 or PTPN2 inhibitor treatment, such as cancer or metabolic diseases.
Owner:NERIO THERAPEUTICS INC

Protein tyrosine phosphatase degraders and uses thereof

PCT designated stage expiredWO2025030006A2Organic active ingredientsOrganic chemistryDiseasePTPN1
Provided herein are degrader compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions favorably responsive to PTPN1 or PTPN2 degrader treatment, e.g., a cancer or a metabolic disease.
Owner:NERIO THERAPEUTICS INC

Fatty acylation BimBH3 analogue containing D-type amino acid as well as preparation method and application of fatty acylation BimBH3 analogue

The invention discloses a BimBH3 analogue containing D-type amino acid and N-terminal fatty acid acylation, a preparation method of the BimBH3 analogue and application of the BimBH3 analogue as a PTPN1 inhibitor to development of hypoglycemic drugs. The structural general formula of the novel BimBH3 mimic peptide analogue is shown as a formula I: # imgabs0 #, wherein Raa2 is equal to D-His, D-Leu, D-Pro, D-Ser, D-Arg, D-Gln, D-Lys, D-Trp, D-Val, D-Tyr, D-Ala, Raa3 is equal to D-Gln, Raa7 is equal to D-Arg, and Raa8 is equal to D-Allo-Ile. The mimic peptide compound is derived from a core region of a Bim-BH3 structural domain, different D-type amino acid site-specific replacement modification and N-terminal conjugated hexadecanoic acid modification are adopted for amino acids at the second, third, seventh and eighth sites respectively, the BimBH3 mimic peptide modified by the D-type amino acid is more stable and has higher metabolic stability, and the target binding capacity and inhibitory activity of the BimBH3 mimic peptide can still be reserved or even improved. The BimBH3 mimic peptide compound shows an excellent PTPN1 inhibitor, the ability of resisting protease hydrolase and various digestive enzymes is also remarkably improved, and the BimBH3 mimic peptide compound has longer pharmacological action time and can play a potential long-acting hypoglycemic role through subcutaneous injection or oral administration. The compound is completely prepared by a polypeptide solid-phase synthesis method, and an obtained crude product is subjected to semi-preparative liquid chromatography purification and freeze-drying to obtain a target compound.
Owner:QINGDAO UNIV OF SCI & TECH

Protein tyrosine phosphatase inhibitor combinations

PCT designated stage expiredWO2025030008A1Inorganic active ingredientsAntibody ingredientsProtein Tyrosine Phosphatase Non-Receptor TypeDisease
Provided herein are methods using a combination comprising a protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and an additional therapeutic agent for treating diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
Owner:NERIO THERAPEUTICS INC

Thiadiazolidinone derivative as well as preparation method and application thereof

The invention discloses a thiadiazolidinone compound and a preparation method and application thereof, the thiadiazolidinone derivative is a compound with a structure shown as a general formula (I) or pharmaceutically acceptable salt of the compound, and the invention further discloses application of the thiadiazolidinone derivative in medicine for treating PTPN2 / PTPN1 mediated diseases. The compound disclosed by the invention has obvious inhibitory activity on PTPN2 / PTPN1 phosphatase, has important influence on occurrence and development of tumors and immune response, can also be used in combination with an immunosuppressant to treat related immune diseases, can be developed into an anti-tumor drug with high activity, good selectivity and small toxic and side effects, and has the characteristics of strong plasticity and great future modification potential. # imgabs0 #
Owner:CHINA PHARM UNIV

Protein tyrosine phosphatase inhibitors and uses thereof

Provided herein are compounds, compositions, and methods that are useful for inhibiting protein tyrosine phosphatases, such as protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and that are useful for treating related diseases, disorders, or conditions, such as cancer or metabolic diseases, that respond favorably to treatment with a PTPN1 or PTPN2 inhibitor.
Owner:NERIO THERAPEUTICS INC

Protein tyrosine phosphatase inhibitor as well as pharmaceutical composition and application thereof

The invention belongs to the field of medical chemistry, and particularly discloses a protein tyrosine phosphatase inhibitor, such as type 2 non-receptor protein tyrosine phosphatase (PTPN2) and / or type 1 non-receptor protein tyrosine phosphatase (PTPN1) inhibitor, a pharmaceutical composition and application thereof. The invention discloses a method for treating related diseases such as cancers and metabolic diseases by using the protein tyrosine phosphatase inhibitor.
Owner:ALICORN PHARMACEUTICAL CO LTD

Inhibitors of PTPN2 and / or PTPN1

The present invention relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of PTPN2 and / or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of PTPN2 and / or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to processes for the preparation of said compounds.
Owner:KATHOLIEKE UNIV LEUVEN +2

Compound as PTPN inhibitor

PCT designated stageWO2026037253A1Organic chemistryMetabolism disorderDiseasePTPN1
Provided in the present invention is a class of compounds. Specifically, provided in the present invention is a compound having a structure as shown in the following formula (I), or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, or solvate thereof. The compound is capable of effectively inhibiting PTPN2 and / or PTPN1, and can be used for treating or preventing diseases or conditions associated with the activity or expression level of PTPN2 and / or PTPN1.
Owner:HANGZHOU INNOGATE PHARMA CO LTD +1

NEW COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES

UndeterminedDOP2026000004ADiseasePTPN1
The present invention relates to novel compounds of Formulas (I) and (III), with said compounds for use as a medicament, more particularly for the prevention or treatment of diseases mediated by PTPN2 and / or PTPN1 activity, and even more particularly for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to a method for the prevention or treatment of such diseases comprising the use of the novel compounds. The present invention further relates to pharmaceutical compositions or combination preparations of the novel compounds, as well as to said compositions or preparations for use as a medicament, most preferably for the prevention or treatment of diseases mediated by PTPN2 and / or PTPN1 activity, and even more particularly for the prevention or treatment of cancer or metabolic diseases.The invention also relates to processes for the preparation of said compounds.
Owner:KATHOLIEKE UNIV LEUVEN +1

Protein tyrosine phosphatase inhibitor and application thereof

PendingCN119365452AOrganic chemistryMetabolism disorderProtein Tyrosine Phosphatase Non-Receptor TypeDisease
Provided herein are compounds, compositions and methods useful for inhibiting protein tyrosine phosphatase (e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1)) and for treating related diseases, disorders and conditions (e.g., cancer or metabolic diseases) that are advantageously responsive to treatment with PTPN1 or PTPN2 inhibitors.
Owner:NERIO THERAPEUTICS INC

PTPN2 inhibitors

The present invention is generally directed to inhibitors of protein tyrosine phosphatase enzymes (PTPN1 and / or PTPN2) useful in the treatment of diseases and disorders modulated by said enzymes and having the Formula (I):
Owner:MONDEGO BIO LDA

CD40-targeted medicine for realizing tumor immunodiagnosis and treatment by regulating PTPN1 / PTPN2 as well as preparation method and application of CD40-targeted medicine

The invention provides a CD40 targeted medicine for realizing tumor immunodiagnosis and treatment by regulating PTPN1 / PTPN2 as well as a preparation method and application of the CD40 targeted medicine. The drug comprises a drug-loading membrane layer, perfluorinated compound PFC and glycerin are wrapped in the drug-loading membrane layer, the drug-loading membrane layer is coupled with a CD40 agonist, and the drug-loading membrane layer comprises phospholipid, cholesterol, a functionalized lipid polymer and AC484. The drug shows excellent biological stability and can be delivered to tumor tissue through a respiratory tract or a vein route; according to the medicine, accumulation and distribution of the medicine in the body are dynamically monitored through a 1H / 19F magnetic resonance imaging technology, noninvasive evaluation of the tumor state is achieved, immunotherapy is accurately guided, and therefore the tumor treatment effect is remarkably improved.
Owner:HARBIN MEDICAL UNIVERSITY

BimBH3 analogue of double-site coupling fatty acid as well as preparation method and application of BimBH3 analogue

The invention discloses a BimBH3 mimic peptide analogue of double-site coupling fatty acid, a preparation method of the BimBH3 mimic peptide analogue and application of the BimBH3 mimic peptide analogue serving as a novel PTPN1 inhibitor to development of long-acting hypoglycemic drugs. The structural general formula of the Bim BH3 mimic peptide analogue is as shown in formula I: # imgabs0 # mimic peptide compound is derived from a core region of a BimBH3 structural domain, the second amino acid is replaced and modified by Fmoc-Lys (Dde)-OH, the N end of a peptide chain is conjugated and modified by fatty monoacid or fatty diacid, the amino group of a side chain of lysine is conjugated and modified by fatty diacid, and the amino group of the side chain of lysine is conjugated and modified by fatty diacid. The compound has better metabolic stability, membrane permeability, pharmacokinetic characteristics and longer pharmacological action time, and shows an excellent long-acting hypoglycemic effect in the body of a type 2 diabetes mellitus model mouse. The compound is prepared by adopting a polypeptide solid-phase synthesis method, and a crude product is purified and freeze-dried to obtain a target compound.
Owner:QINGDAO UNIV OF SCI & TECH

Degrader Compounds and Uses Thereof

PendingUS20240424111A1Organic chemistryMetabolism disorderProtein Tyrosine Phosphatase Non-Receptor TypeDisease
Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
Owner:CALICO LIFE SCI LLC

1, 2, 5-thiadiazole compound substituted by 4-position tetrahydronaphthalene or tetrahydroisoquinoline structure and application of 1, 2, 5-thiadiazole compound

The invention discloses a 1, 2, 5-thiadiazole compound substituted by a 4-position tetrahydronaphthalene or tetrahydroisoquinoline structure and application of the 1, 2, 5-thiadiazole compound, and belongs to the field of medicines. The invention provides a 4-position tetrahydronaphthalene or tetrahydroisoquinoline structure substituted 1, 2, 5-thiadiazole compound with a structure shown as a formula (I) or a pharmaceutically acceptable salt thereof, and the compound has excellent protein tyrosine phosphatase inhibitory activity and can be used for preparing a medicine for preventing and treating diseases. A method of treatment of a disease or condition (e.g., cancer, type 2 diabetes, obesity, metabolic disease or any other disease, condition or condition) that is positively responsive to a protein tyrosine phosphatase (PTPN2 or PTPN1) inhibitor is provided.
Owner:南京雷正医药科技有限公司

Benzo ring-containing compound as protein tyrosine phosphatase inhibitor, and use thereof

The present invention relates to a benzo ring-containing compound as a PTPN1 and / or PTPN2 inhibitor and use thereof, and particularly relates to a compound of formula (I), a tautomer thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, a method for preparing same, and use thereof in the preparation of a medicament for treating a PTPN1 and / or PTPN2-related disease.
Owner:HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC

Thiomorpholino antisense oligonucleotides for treatment of PTP1B related diseases

The present invention relates to antisense oligonucleotides (ASO) for use in treating, preventing, or ameliorating the progression of conditions such as type 2 diabetes mellitus (T2DM) and insulin resistance, leptin resistance, and obesity, Rater Syndrome, and cancer. Specifically, a thiomorpholino-containing ASO targets a protein tyrosine phosphatase non-receptor type 1 (PTPN1) gene transcript and induces exon skipping (including exon 2) of the transcript during RNA processing, thereby inhibiting expression of the protein tyrosine phosphatase-1B (PTP1B) protein.
Owner:THE REGENTS OF THE UNIVERSITY OF COLORADO +1

Double bond substituent containing compound serving as protein tyrosine phosphatase inhibitor, and use thereof

The present invention relates to a double bond substituent containing compound serving as a PTPN1 and / or PTPN2 inhibitor, and a use thereof, and in particular to a compound represented by formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt thereof, and a preparation method therefor, and a use in the preparation of a drug for treating diseases related to PTPN1 and / or PTPN2.
Owner:WUHAN HUMANWELL INNOVATIVE DRUG RES & DEV CENT LTD CO

Protein tyrosine phosphatase inhibitors and methods of use thereof

To provide compounds and compositions for treating cancer, type-2 diabetes, obesity, a metabolic disease, or any other disease, disorder or ailment favorably responsive to PTPN2 or PTPN1 inhibitor treatment, and methods of treating the diseases.SOLUTION: Provided herein are: compounds with an effect of inhibiting PTPN2 and / or PTPN1 illustrated by the compound Y in the figure; pharmaceutically acceptable compositions comprising the compounds and pharmaceutically acceptable carriers; and methods of treatment by administering the compositions.SELECTED DRAWING: None
Owner:CALICO LIFE SCI LLC +1

Benzoring-containing compound serving as protein tyrosine phosphatase inhibitor and application of benzoring-containing compound

The invention relates to a benzoring-containing compound serving as a PTPN1 and / or PTPN2 inhibitor and application thereof, in particular to a compound shown in a formula (I), a tautomer, a stereoisomer or pharmaceutically acceptable salt of the compound, a preparation method of the compound, and application of the compound to preparation of drugs for treating PTPN1 and / or PTPN2 related diseases. (I)
Owner:HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC

Protein tyrosine phosphatase inhibitors and uses thereof

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
Owner:NERIO THERAPEUTICS INC

Protein tyrosine phosphatase degradation agent and application thereof

Provided herein are useful for degrading protein tyrosine phosphatase, such as protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and useful for treating related diseases, disorders and conditions that contribute to the treatment of PTPN1 or PTPN2 degrading agents, degradation agent compounds, compositions, and methods for treating cancer, such as cancer or metabolic diseases.
Owner:NERIO THERAPEUTICS INC

Inhibitors of PTPN 2 / PTPN1 tyrosine phosphatase

The present invention relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of PTPN2 and / or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of PTPN2 and / or PTPN1, yet more in particular for the prevention or treatment of cancer or metabolic diseases. The present invention also relates to processes for the preparation of said compounds.
Owner:KATHOLIEKE UNIV LEUVEN +1

Double-bond substituted compound as protein tyrosine phosphatase inhibitor and application thereof

The invention relates to a compound containing double bond substitution as a PTPN1 and / or PTPN2 inhibitor and application thereof, in particular to a compound shown in a formula (I), a tautomer, a stereoisomer or pharmaceutically acceptable salt of the compound, a preparation method of the tautomer, the stereoisomer or the pharmaceutically acceptable salt of the compound, and application of the tautomer, the stereoisomer or the pharmaceutically acceptable salt in preparation of drugs for treating PTPN1 and / or PTPN2 related diseases.
Owner:WUHAN HUMANWELL INNOVATIVE DRUG RES & DEV CENT LTD CO +1

Combinations of protein tyrosine phosphatase inhibitors

Provided herein are methods of using a combination comprising protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1) and an additional therapeutic agent to treat a disease (e.g., cancer or metabolic disease) that produces an advantageous response to PTPN1 or PTPN2 inhibitor treatment.
Owner:NERIO THERAPEUTICS INC

Novel BimBH3 mimic peptide analogue constructed based on nailing and fatty acid acylation double modification strategy as well as preparation method and application of novel BimBH3 mimic peptide analogue

The invention discloses a novel BimBH3 mimic peptide analogue constructed on the basis of a nailing and fatty acid acylation dual-modification strategy and application of the novel BimBH3 mimic peptide analogue serving as a PTPN1 inhibitor to development of a long-acting hypoglycemic drug. The structural general formula of the BimBH3 mimic peptide analogue is as shown in a formula I. The structural general formula of the BimBH3 mimic peptide analogue is as shown in a formula I. The invention provides the BimBH3 mimic peptide analogue with a novel structure, and the BimBH3 mimic peptide analogue is constructed by adopting a nailing and fatty acid acylation dual-modification strategy and has the structural general formula as shown in the formula I. The invention further provides a preparation method of the BimBH3 mimic peptide analogue. On the basis of a BimBH3 functional domain core sequence, the novel BimBH3 mimic peptide analogue has target inhibitory activity, metabolic stability and in-vivo action durability through second-site lysine substitution, N-terminal palmitic acid conjugation and fifth, sixth and ninth site glutamic acid side chain mediated synthesis ring nailing modification, and the synthesis ring nailing mode is molecular lactam cyclization. Experiments show that the compound can efficiently inhibit PTPN1 activity, has a long-acting hypoglycemic effect in a type 2 diabetes animal model, and has the potential of being developed into a long-acting antidiabetic drug which is administered once a week. The invention also discloses a solid-phase synthesis preparation method of the compound and application of the compound as a potential PTPN1 inhibitor drug.
Owner:QINGDAO UNIV OF SCI & TECH

PTPN2 inhibitors

PendingAU2023269777B2DiseasePTPN1
The present invention is generally directed to inhibitors of protein tyrosine phosphatase enzymes (PTPN1 and / or PTPN2) useful in the treatment of diseases and disorders modulated by said enzymes and having the Formula (I). Further disclosed a method of treating a disease or disorder associated with PTPN1 / PTPN2, comprising of administering to a subject a compound or a pharmaceutical composition.
Owner:MONDEGO BIO LDA